Serum magnesium concentration may predict no-reflow phenomenon in primary angioplasty for ST-elevation myocardial infarction

2020 ◽  
Vol 33 (4) ◽  
pp. 123-130
Author(s):  
Eser Açıkgöz ◽  
Sadık Kadri Açıkgöz ◽  
Gökhan Çiçek
Keyword(s):  
Myocardial Infarction ◽  
Serum Magnesium ◽  
Primary Angioplasty ◽  
St Elevation Myocardial Infarction ◽  
Magnesium Concentration ◽  
Serum Magnesium Concentration ◽  
No Reflow ◽  
No Reflow Phenomenon ◽  
St Elevation

Assessment of no-reflow phenomenon in patients with acute ST-elevation myocardial infarction

2021 ◽  
Vol 27 (1) ◽  
pp. 39
Author(s):  
D. V. Krinochkin ◽  
I. S. Bessonov ◽  
E. I. Iaroslavskaia ◽  
V. A. Kuznetsov
Keyword(s):  
Myocardial Infarction ◽  
St Elevation Myocardial Infarction ◽  
No Reflow ◽  
No Reflow Phenomenon ◽  
St Elevation

scholarly journals Association between Endothelial Nitric Oxide Synthase Gene Polymorphism (Glu298Asp) and Coronary No-Reflow Phenomenon in Acute Myocardial Infarction

2019 ◽  
Vol 73 ◽  
pp. 529-535
Author(s):  
Ahmet Arif Yalcin ◽  
Ismail Biyik ◽  
Faruk Akturk ◽  
Veysel Sabri Hancer ◽  
Burce Yalcin ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Myocardial Infarction ◽  
Nitric Oxide Synthase ◽  
Endothelial Nitric Oxide Synthase ◽  
St Elevation Myocardial Infarction ◽  
No Reflow ◽  
No Reflow Phenomenon ◽  
St Elevation ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide

No-reflow phenomenon is an important complication of primary percutaneous coronary intervention. Several variants in the endothelial nitric oxide synthase gene, which reduce endothelial nitric oxide synthase activity, are a risk factor for coronary heart disease. However, its role in no-reflow phenomenon has not yet been revealed. This study aimed to investigate whether there is a relationship between endothelial nitric oxide synthase Glu298Asp gene variant and the development of coronary no-reflow phenomenon in patients with ST elevation myocardial infarction. The study was conducted among 116 patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. Group 1 included 52 ST elevation myocardial infarction patients undergoing no-reflow phenomenon as a study group. Group 2 comprised 64 ST elevation myocardial infarction patients without no-reflow phenomenon as a control group. Endothelial nitric oxide synthase was tested using polymerase chain reaction-restriction fragment length variant. The prevalence of TT genotype of endothelial nitric oxide synthase Glu298Asp gene variant was found to be significantly higher in patients developing coronary no-reflow when compared to those without no-reflow (p = 0.016; 11.54% vs. 1.56%) (OR = 10.85, 95% CI = 1.22–96.39). However, a similar association for the heterozygous GT genotype of endothelial nitric oxide synthase Glu298Asp gene variant was not observed between the two groups. The results of this preliminary study indicate that there is an association between Glu298Asp variant in endothelial nitric oxide synthase gene and the development of no-reflow phenomenon in ST elevation myocardial infarction. The presence of homozygous TT allele may contribute to tendency to the development of no-reflow phenomenon.

Sign in / Sign up

Export Citation Format

Share Document